...
首页> 外文期刊>Haematologica >The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy | Haematologica
【24h】

The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy | Haematologica

机译:缓解后化疗后,通过流式细胞术检测异基因干细胞移植对年轻急性髓样白血病患者的预后的影响血液学

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Minimal residual disease (MRD) levels were determined by multi-parameter flow cytometry in 45 younger adult patients ( pound60 years old) with acute myeloid leukemia (AML) in complete remission. Data were collected after induction (MRD1; n=43) and/or at the end of post-remission chemotherapy or before stem cell transplantation (SCT)(MRD2; n=31). Patients with detectable MRD2 who underwent allogeneic or autologous SCT had significantly better 5-year relapse-free survival than patients not transplanted (80%, 53% and 0%, respectively p=0.003). Therefore allogeneic SCT should be considered in younger adult AML patients with detectable MRD at the end of post-remission chemotherapy. Autologous SCT may be an alternative for patients not eligible for allogeneic SCT.
机译:通过多参数流式细胞术确定了45例完全缓解的急性髓细胞白血病(AML)的年轻成人患者(60岁)的最小残留疾病(MRD)水平。在诱导后(MRD1; n = 43)和/或缓解后化疗结束时或干细胞移植(SCT)之前收集数据(MRD2; n = 31)。接受同种异体或自体SCT的可检测MRD2患者比未移植患者具有更好的5年无复发生存率(分别为80%,53%和0%,p = 0.003)。因此,在缓解后化疗结束后,对于可检测到MRD的年轻成人AML患者,应考虑同种异体SCT。对于不符合同种异体SCT资格的患者,自体SCT可能是另一种选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号